Kejun J. Nan
No. 277 Yanta West Road
Xi'an, 710061, China
Xi'an, 710061, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
Journal: Experimental hematology & oncology
Published: December 23, 2025
Circ-malat1 promotes gastric cell growth via miR-154-5p/CCND2.
Journal: Frontiers in genetics
Published: March 15, 2025
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.
Journal: Cancer communications (London, England)
Published: November 27, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 01, 2024
Retraction: miRNA-302b Suppresses Human Hepatocellular Carcinoma by Targeting AKT2.
Journal: Molecular cancer research : MCR
Published: July 29, 2024
Retraction Note: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 18, 2023
First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions.
Journal: Immunotherapy
Published: March 09, 2022
Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017.
Journal: Annals of medicine
Published: February 24, 2022
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Journal: Translational lung cancer research
Published: February 18, 2022
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Journal: Thoracic cancer
Published: February 26, 2021
Colon cancer cells secreted CXCL11 via RBP-Jκ to facilitated tumour-associated macrophage-induced cancer metastasis.
Journal: Journal of cellular and molecular medicine
Published: February 03, 2021
Circ_0000218 plays a carcinogenic role in laryngeal cancer through regulating microRNA-139-3p/Smad3 axis.
Journal: Pathology, research and practice
Published: May 18, 2020
Last Updated: 09/26/2026